Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-nmvwc Total loading time: 0 Render date: 2024-06-16T05:46:51.432Z Has data issue: false hasContentIssue false

Serotonin/Norepinephrine Reuptake Inhibitor Antidepressants

from Part II - Medication Reference Tables

Published online by Cambridge University Press:  19 October 2021

Edited by
Michael Cummings  and
Stephen Stahl
Michael Cummings
Affiliation:
University of California, Los Angeles
Stephen Stahl
Affiliation:
University of California, San Diego
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Management of Complex Treatment-resistant Psychotic Disorders , pp. 273 - 289
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Alembic Pharmaceuticals Limited. (2019). Desvenlafaxine Package Insert. Vadodara (India).Google Scholar
Deecher, D. C., Beyer, C. E., Johnston, G., et al. (2006). Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther, 318, 657–665.CrossRefGoogle ScholarPubMed
Gaynes, B. N., Rush, A. J., Trivedi, M. H., et al. (2008). The STAR*D study: treating depression in the real world. Clevel Clin J Med, 75, 57–66.CrossRefGoogle ScholarPubMed
Soares, C. N., Endicott, J., Boucher, M., et al. (2014). Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder. CNS Spectr, 19, 519–527.CrossRefGoogle ScholarPubMed
Preskorn, S., Patroneva, A., Silman, H., et al. (2009). Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol, 29, 39–43.CrossRefGoogle ScholarPubMed

References

Aurobindo Pharma Limited. (2019). Duloxetine Package Insert. East Windsor, New Jersey.Google Scholar
Stahl, S. M., Grady, M. M., Moret, C., et al. (2005). SNRIs: the pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr, 10, 732–747.CrossRefGoogle ScholarPubMed
Hirschfeld, R. M., Mallinckrodt, C., Lee, T. C., et al. (2005). Time course of depression-symptom improvement during treatment with duloxetine. Depress Anxiety, 21, 170–177.CrossRefGoogle ScholarPubMed
Brannan, S. K., Mallinckrodt, C. H., Brown, E. B., et al. (2005). Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res, 39, 43–53.CrossRefGoogle ScholarPubMed
Cipriani, A., Koesters, M., Furukawa, T. A., et al. (2012). Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev, 10, CD006533.Google Scholar

References

Amneal Pharmaceuticals LLC. (2019). Levomilnacipran Package Insert. Bridgewater, New Jersey.Google Scholar
Auclair, A., Martel, J., Assié, M., et al. (2013). Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacol, 70, 338–347.CrossRefGoogle ScholarPubMed
McIntyre, R. S., Gommoll, C., Chen, C., et al. (2016). The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials. CNS Spectr, 21, 385–392.CrossRefGoogle ScholarPubMed
Papakostas, G. I., Fava, M. (2007). A meta-analysis of clinical trials comparing milnacipran, a serotonin–norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Eur Neuropsychopharmacol, 17, 32–36.CrossRefGoogle ScholarPubMed

References

Aurobindo Pharma Limited. (2019). Venlafaxine Package Insert. East Windsor, New Jersey.Google Scholar
Aurobindo Pharma Limited. (2019). Venlafaxine Extended Release Package Insert. East Windsor, New Jersey.Google Scholar
Stahl, S. M., Grady, M. M., Moret, C., et al. (2005). SNRIs: the pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr, 10, 732–747.Google Scholar
Benkert, O., Gründer, G., Wetzel, H., et al. (1996). A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res, 30, 441–451.Google Scholar
Gaynes, B. N., Rush, A. J., Trivedi, M. H., et al. (2008). The STAR*D study: treating depression in the real world. Clevel Clin J Med, 75, 57–66.CrossRefGoogle ScholarPubMed
Cipriani, A., Furukawa, T. A., Salanti, G., et al. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet, 373, 746–758.CrossRefGoogle ScholarPubMed
Preskorn, S. H. (2010). Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters. J Psychiatr Prac, 16, 46–49.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×